Stock Information
Roivant Sciences Ltd (ROIV)
Ticker Symbol: ROIV
Exchange: NASDAQ
Sector: Biotechnology
Market Cap: $20,127.53 mil
Piotroski score: 2
PE Ratio: N/A
EPS (TTM): -1.1684
Revenue (TTM): $0.02 M
Dividend Yield: N/A%
ROE: -18.32%
Latest News
-
Reported Saturday, Roivant's Priovant Therapeutics Wins FDA Priority Review For Brepocitinib After Phase 3 VALOR Trial Meets Primary And All Nine Key Secondary Endpoints In Dermatomyositis
Mon, Mar 30, 2026 2:46 AM
-
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
Sat, Mar 28, 2026 7:00 PM
-
Bernstein Initiates Coverage of Roivant Sciences Ltd. (ROIV) with an Outperform Rating
Wed, Mar 25, 2026 5:00 PM
Key Financials
Financial data not available
